Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...

By analysing MRI scans and a simple blood test from hundreds of patients, researchers identified patterns that reveal how ...

Two new sub-types of multiple sclerosis (MS) were discovered by researchers from Queen Square Analytics and University ...

Using artificial intelligence (AI), researchers looked at brain scans and tested for a blood marker for nerve cell injury and ...

Researchers say the more they find out, the more likely 'we will be able to find treatments that can stop disease progression ...

Researchers say the more they find out, the more likely 'we will be able to find treatments that can stop disease progression ...

Scientists from UCL have used artificial intelligence to discover two new biological sub-types of multiple sclerosis ...

On December 24, 2025, Sanofi announced that the US Food and Drug Administration issued a complete response letter for its new drug application for tolebrutinib to treat non-relapsing secondary ...

Exclusive: Scientists uncovered biological strands using artificial intelligence and hope discovery will revolutionise treatment ...

That scuppered Sanofi's plans for filing tolebrutinib in PPMS, and the FDA has now slammed the brakes on its efforts to get ...

A mother and daughter share a unique therapy experience as graduate student helps her mother navigate communication ...

Sanofi (NASDAQ:SNY) is included among the 15 Global Dividend Stocks to Diversify Your Portfolio. Sanofi (NASDAQ:SNY) said on ...